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2014, accepted Janoronary artery calciﬁcation (CAC) is a risk factor for adverse outcomes in the general population and in patients
with coronary artery disease. The pathogenesis of CAC and bone formation share common pathways, and risk
factors have been identiﬁed that contribute to the initiation and progression of CAC. Efforts to control CAC with
medical therapy have not been successful. Event-free survival is also reduced in patients with coronary calciﬁcation
after both percutaneous coronary intervention (PCI) and bypass graft surgery. Although drug-eluting stents and
devices for plaque modiﬁcation have modestly improved outcomes in calciﬁed vessels, adverse event rates are still
high. Innovative pharmacologic and device-based approaches are needed to improve the poor prognosis of patients
with CAC. (J Am Coll Cardiol 2014;63:1703–14) ª 2014 by the American College of Cardiology FoundationCoronary artery calciﬁcation (CAC) results in reduced
vascular compliance, abnormal vasomotor responses, and
impaired myocardial perfusion (1,2). The presence of CAC
is associated with worse outcomes in the general population
and in patients undergoing revascularization (3,4). The
present paper will review the pathogenesis of CAC and its
impact on the prognosis and treatment of patients with
coronary artery disease (CAD).
Pathophysiology and Risk Factors
Calcium regulatory mechanisms that affect bone formation
and growth also inﬂuence CAC. Alkaline phosphatase is
central to early calcium deposition and has been proposed as
a molecular marker of vascular calciﬁcation (5,6). Vascular
smooth muscle cells (VSMCs) produce matrix vesicles,
which regulate mineralization in the vascular intima and
media (5,7). Other cell types (e.g., microvascular pericytes
and adventitial myoﬁbroblasts) have the potential to
generate mineralized matrix and undergo osteoblastic dif-
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uary 14, 2014.Two recognized types of CAC are atherosclerotic and
medial artery calciﬁcation. Atherosclerotic calciﬁcation
chieﬂy occurs in the intima (5). Inﬂammatory mediators and
elevated lipid content within atherosclerotic lesions induce
osteogenic differentiation of VSMCs (7). Conversely, CAC
in the media is associated with advanced age, diabetes, and
chronic kidney disease (CKD) (6). Previously thought to be
a benign process, medial calciﬁcation contributes to arterial
stiffness, which increases risk for adverse cardiovascular
events (2).
The extent of CAC correlates with plaque burden (8).
Microcalciﬁcations in the ﬁbrous cap might promote
cavitation-induced plaque rupture (9). Additionally, calciﬁc
nodules might disrupt the ﬁbrous cap, leading to thrombosis
(10). Recurrent plaque rupture and hemorrhage with subse-
quent healing might result in the development of obstructive
ﬁbrocalciﬁc lesions and are frequently found in patients with
stable angina and sudden coronary death (10,11).
A number of risk factors contribute to the development
of CAC (Table 1). CAC might be inherited through both
common allelic variants (e.g., chromosome 9p21) and rare
mutations in phosphate metabolism that have also been
associated with myocardial infarction (MI) (12–14). Certain
microribonucleic acids have also been implicated in CAC
development (15), and their dysregulation has been associ-
ated with VSMC transition to an osteoblast-like phenotype
(15).
Patients with CKD have greater cardiovascular morbidity
and mortality, largely due to the presence of CAC and
accelerated atherosclerosis. Hypercalcemia and hyper-
phosphatemia promote CAC. In addition to affecting the
calcium-phosphate solubility equilibrium, phosphate can
stimulate osteochondrogenic transformation of VSMCs
Table 1 Risk Factors for Coronary Calciﬁcation
Risk Factor Intimal Calciﬁcation Medial Calciﬁcation
Advanced age Yes Yes
Diabetes mellitus Yes Yes
Dyslipidemia Yes No
Hypertension Yes No
Male Yes No
Cigarette smoking Yes No
Renal etiology
Dysfunction (YGFR) No Yes
Hypercalcemia No Yes
Hyperphosphatemia Yes Yes
PTH abnormalities No No
Duration of dialysis No Yes
Modiﬁed with permission from Goodman et al. (123).
GFR ¼ glomerular ﬁltration rate; PTH ¼ parathyroid hormone.
Abbreviations
and Acronyms
BMS = bare-metal stent(s)
CABG = coronary artery
bypass graft surgery
CAC = coronary artery
calciﬁcation
CBA = cutting balloon
atherotomy
CKD = chronic kidney
disease
CT = computed tomography
DES = drug-eluting stent(s)
HU = Hounsﬁeld units
LCA = laser coronary
atherectomy
MACE = major adverse
cardiovascular event(s)
MI = myocardial infarction
OA = orbital atherectomy
PES = paclitaxel-eluting
stent(s)
RA = rotational atherectomy
VSMC = vascular smooth
muscle cell
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1704(6,16). Secondary hyperparathy-
roidism in CKD is also a risk
factor for CAC (5), and dialysis
in younger individuals is associ-
ated with similar calcium levels as
with advanced age (17). Addi-
tionally, the renin-angiotensin-
aldosterone system might play a
role in medial artery calciﬁcation,
because angiotensin II type-1
receptor blockers abolished
CAC development in a pre-clinical
model (18).
In diabetic individuals, advanced
glycation end-products might
promote mineralization of micro-
vascular pericytes, and tight gly-
cemic control might slow CAC
in type 1 (but not type 2) diabetes
(7,19). Moreover, the transcrip-
tion factor proliferator-activated
receptor gamma might deter cal-
ciﬁcation by inhibiting Wnt5a-
dependent signaling in VSMCs
(20,21).
The receptor activator of nu-clear factor-kappaB ligand/osteoprotegerin pathway has
emerged as a potential link between osteoporosis and CAC
(5). Osteoprotegerin acts as a decoy receptor, which coun-
teracts the pro-osteoclastic and bone resorptive effects of the
receptor activator of nuclear factor-kappa pathway (5). Mice
deﬁcient in osteoprotegerin experience increased calciﬁca-
tion and plaque progression (22). However, human epide-
miologic data suggest that higher osteoprotegerin levels are
associated with CAC and cardiovascular events (23). Further
study is required to elucidate the role of this pathway in
CAC pathogenesis.
Interestingly, ingestion of a high-calcium diet has not
been associated with CAC (24), and no relationship has
been observed between dietary calcium intake and CAD
(25). These data suggest that CAC is the result of aberrant
regulatory mechanisms rather than simple calcium overload.
Enhanced understanding of the pathways that contribute
to CAC is needed if more effective therapies are to be
developed.
Prevalence, Detection, and Prognosis
The prevalence of CAC is age- and sex-dependent, occur-
ring in 90% of men and 67% of women older than
70 years of age (26,27). Additionally, CAC is most frequent
in Caucasians (28). The extent of CAC strongly correlates
with the degree of atherosclerosis and the rate of future
cardiac events (29–31).
Computed tomography (CT) is the only noninvasive test
with high sensitivity and speciﬁcity for calcium detectionand is capable of quantifying calciﬁcation (32). In large-scale
observational studies, CT-scan–based calcium scores
added prognostic value for predicting cardiac death and
MI, especially in patients at intermediate risk for events
(Fig. 1) (29,33–35). As a result, the most recent American
College of Cardiology/American Heart Association guide-
lines note that noninvasive measurement of CAC score is
reasonable for cardiovascular risk assessment in asymptom-
atic patients at intermediate risk (those with a 10% to 20%
rate of coronary events over 10 years; class IIa, Level of
Evidence: B) (36). Interpretation and utility of CAC scores
is dependent on the underlying risk proﬁles of patients for
CAD (37).
As the CAC score increases, it loses sensitivity and gains
speciﬁcity for predicting CAD (38,39). A CAC score of
>0 Hounsﬁeld units (HU) suggests some underlying athero-
sclerosis, whereas scores 100 and 400 HU should prompt
risk factor modiﬁcation and further diagnostic evaluation,
respectively (40). Asymptomatic persons without traditional
risk factors but with a documented CAC score 400 HU
might have a worse cardiovascular prognosis than those
with 3 risk factors but no CT-detected CAC (41).
Coronary angiography has low-moderate sensitivity
compared with grayscale intravascular ultrasound (IVUS)
and CT for detection of CAC but is very speciﬁc (high
positive predictive value) (38,42,43). Angiographic CAC
is often classiﬁed into 3 groups: none/mild, moderate, and
severe. Severe calciﬁcation is most commonly deﬁned as
radiopacities seen without cardiac motion before contrast
injection, usually affecting both sides of the arterial lumen
(Fig. 2), and moderate calciﬁcation as radiopacities noted
only during the cardiac cycle before contrast injection (44).
Intravascular ultrasound is substantially more accurate
than cineangiography for CAC detection, with sensitivity
of 90% to 100% and speciﬁcity of 99% to 100% (45,46).
The signature of calciﬁed plaque on grayscale IVUS is a
bright echo with acoustic shadowing (47), and the extent
of calciﬁcation can be graded by several metrics. The arc
of calcium is classiﬁed as none, 1 quadrant (0 to 90),
Figure 1 Select Studies Demonstrating Improved Risk Stratiﬁcation of CHD Events With Use of CAC Scores
(A) With data from the MESA (Multi-Ethnic Study of Atherosclerosis) (35), a demonstration that the addition of the coronary artery calciﬁcation (CAC) score to Framingham risk
factors (age, sex, smoking, systolic blood pressure, use of antihypertensive medications, and lipid status) led to an improvement in prediction of coronary heart disease (CHD)
events. Speciﬁcally, there was a signiﬁcant shift in the number of patients reclassiﬁed from intermediate (3% to 10% risk of CHD events in 5 years) to high risk (>10% risk of
CHD events in 5 years). (B) Similar ﬁndings are presented from the Rotterdam study (33). With the addition of CAC scores to a reﬁtted Framingham model, 52% of men and
women from the intermediate-risk group were reclassiﬁed to a different risk category.
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17052 quadrants (91 to 180), 3 quadrants (181 to 270), or
4 quadrants (271 to 360). Calcium location is deﬁned as
superﬁcial if present in the intimal-luminal interface, deepFigure 2 Example of Severe Coronary Artery Calciﬁcation as Assess
Example of severe coronary artery calciﬁcation as assessed by angiography before (A) a
coronary artery, visible on the still image of A (arrows).if within the medial-adventitial border or closer to the
adventitia than the lumen, or both superﬁcial and deep.
Deposits can be assessed relative to the thickest plaqueed by Angiography
nd after (B) contrast injection. Note the presence of calcium on both sides of the
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1706accumulation as concordant (center of calcium arc 45 of
thickest plaque accumulation), perpendicular (center of cal-
cium arc 45 to 135 from thickest plaque accumulation),
or opposite (center of arc of calcium 135 from thickest
plaque accumulation). Finally, the calcium length can be
measured (Fig. 3) (42,48). However, because ultrasound
does not penetrate calcium, calcium thickness cannot be
determined, and volume cannot be calculated.
Radiofrequency analysis of the IVUS signal allows for
in vivo characterization of coronary plaque components,
including ﬁbrotic plaque, ﬁbrofatty plaque, necrotic core, and
dense calcium (49). In the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) study in which 3-vessel coronary radiofrequency IVUS
was performed, patients with the highest dense calcium vol-
umes were more likely to have high-risk atherosclerotic fea-
tures and had the highest 3-year rates of major adverse
cardiovascular events (MACE), although not necessarily
arising from the calciﬁed plaque itself (50–52).
Optimal coherence tomography (OCT) provides higher-
resolution imaging (10 to 20 mm) than grayscale IVUS
(150 to 200 mm). Optimal coherence tomography detects
calcium as low-intensity, low-attenuation areas with sharp
borders (Fig. 3) (53). The sensitivity (95% to 100%) and
speciﬁcity (97% to 100%) of OCT for CAC rival that of
IVUS (46,53). Moreover, because light penetrates calcium,
OCT can in many cases assess calcium thickness and mea-
sure calcium volume (54).
Integrating anatomical and functional information will
likely improve upon the prognostic utility of established
imaging techniques. In a recent study that combined
single-photon emission computed tomography myocardial
perfusion imaging with CAC scoring, overlapping regions
with both calciﬁcation and poor perfusion strongly pre-
dicted MACE (55). Dweck et al. (56) have employed
radiolabeled 18F-sodium ﬂuoride to visualize regions of
active inﬂammation and calciﬁcation on positron emission
tomography, offering the promise to detect pre-clinical
CAC to facilitate earlier diagnosis, risk factor modiﬁcation,
and/or treatment.Therapies for CAC
Medical therapy. Several studies have examined whether
medical therapy can halt or even reverse CAC progression
(Table 2). In the St. Francis Heart Study, 1,005 patients
with calcium scores 80th percentile for age and sex were
randomized to atorvastatin 20 mg daily or placebo (57).
Atorvastatin resulted in reduced low-density lipoprotein
levels and a nonsigniﬁcant decline in MACE with no effect,
however, on CAC progression. Although selective renin-
angiotensin-aldosterone system inhibition does not seem
to signiﬁcantly reduce CAC (58), no studies have investi-
gated whether modulating the receptor activator of nuclear
factor-kappaB or proliferator-activated receptor gamma
pathways inﬂuences CAC in humans.Calcium-channel blockers (59), hormonal therapy (60),
phosphate binders (61,62), and most recently medicinal
supplements (63,64) have all been suggested to reduce CAC
progression in small randomized trials and prospective
studies. Larger prospective trials are required to deﬁnitively
evaluate these approaches before they can be recommended.
Percutaneous coronary intervention 1: balloon angioplasty
and stents. CAC increases the likelihood of procedural
failure and complications after balloon angioplasty (65,66).
Noncompliant calciﬁed plaques often require high-pressure
dilation, increasing the risk for coronary dissection and
thrombosis (66–68). Moreover, the force (tension) applied
from the balloon to the vessel wall might not be uniform
across the length of the lesion, due to varying amounts of
calciﬁcation, further increasing the risk for dissection and
acute vessel closure, MI, restenosis, and MACE (69–72).
Extensive calciﬁcation in severely obstructive lesions impedes
device delivery and increases the risk of procedural failure
(73–75). As such, angiographic measures of procedural
success, such as acute gain and diameter stenosis, are often
worse in calciﬁed lesions (66,68,76). Calciﬁed lesions are
also associated with particulate embolization, resulting in
increased rates of peri-procedural myonecrosis (77,78).
Although implantation of bare-metal stents (BMS)
compared with balloon angioplasty improves acute and long-
term event-free survival in both calciﬁed and noncalciﬁed
lesions, stent underexpansion, asymmetric expansion, and
malapposition are frequently observed in heavily calciﬁed
lesions (4,68,77). Eccentric compared with concentric
calciﬁcation is associated with less acute gain and noncircular
stent geometry (68). Stent underexpansion in particular in-
creases the risk for complications, including restenosis and
stent thrombosis (4,79,80).
Several studies have shown that drug-eluting stents
(DES) are more effective than BMS in calciﬁed lesions
(Table 3). Less neointimal hyperplasia in calciﬁed (and
noncalciﬁed) lesions after DES compared with BMS re-
duces angiographic late loss, restenosis, and repeat revascu-
larization (81–85). Moreover, multiple studies have reported
similar rates of stent thrombosis with DES and BMS in
calciﬁed lesions, with comparable rates of death and MI
(74,81–84).
The extent to which CAC contributes to poor outcomes
after DES is controversial. Most studies have reported
comparable rates of stent thrombosis, MI, and death after
percutaneous coronary intervention (PCI) with DES in
calciﬁed and noncalciﬁed coronary arteries (76,81,86,87).
However, data with regard to the absolute efﬁcacy of DES in
calciﬁed lesions are conﬂicting. Small-scale studies have
suggested that the degree of neointimal hyperplasia is similar
in calciﬁed and noncalciﬁed lesions (85,88), suggesting that
the potency of antiproliferative agents might be independent
of CAC. Consistent with these studies are reports showing
similar rates of angiographic restenosis and target lesion
revascularization in DES-treated calciﬁed and noncalciﬁed
lesions (74,86,87). Conversely, other studies have reported
Figure 3 Intravascular Ultrasound Images of Mild, Moderate, and Severe Calciﬁcation
(A to C) Intravascular ultrasound images of mild, moderate, and severe calciﬁcation, visualized as superﬁcial hyperechoic tissue with acoustic shadowing, delimited by the arc
of calciﬁcation relative to the center of the lumen (white arrows). (D to F) Corresponding slices obtained by optimal coherence tomography (OCT). Calciﬁcation by OCT is
visualized as a signal-poor or heterogenous region with sharply delineated borders. Because light (but not sound) can penetrate calciﬁed tissue, the thickness of calciﬁcation
may be evaluated by OCT but not by intravascular ultrasound (white arrow in F).
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1707greater rates of restenosis and repeat revascularization in
DES-treated calciﬁed compared with noncalciﬁed lesions
(76,89). Potential risk factors for restenosis and repeat
revascularization include stent underexpansion, damage of
DES polymer coats by calciﬁed lesions, or adjunctive use of
other devices (e.g., rotational atherectomy [RA]) that might
directly promote neointimal hyperplasia (76,90).
PCI 2: devices to improve vessel compliance. CUTTING
AND SCORING BALLOONS. Cutting and scoring balloons donot remove calcium. They improve vessel compliance by
creating discrete incisions in the atherosclerotic plaque,
enabling greater lesion expansion and reducing recoil while
preventing uncontrolled dissections (91). Studies evaluating
the use of cutting balloon atherotomy (CBA) in calciﬁed
lesions are shown in Table 4. A meta-analysis of 4 ran-
domized CBA versus balloon angioplasty trials (before the
routine stent era) in calciﬁed and noncalciﬁed lesions sug-
gested that CBA is associated with similar rates of restenosis
Table 2 Studies of Medical Therapies for Targeting CAC Progression
First Author (Ref. #) Year N Design Intervention Outcomes
Motro and Shemesh (59) 2001 201 RCT Nifedipine vs. HCTZ/amiloride Nifedipine was associated with signiﬁcantly reduced
coronary calcium progression at 3 years in
hypertensive patients.
Chertow et al. (61) 2002 200 RCT Sevelamer vs. calcium-based
phosphate binder
Sevelamer was associated with signiﬁcantly lower CAC
score progression in hemodialysis patients at 52 weeks.
Arad et al. (57) 2005 1,005 RCT Atorvastatin vs. vitamin C vs.
vitamin E vs. placebo
Treatment arms did not have a signiﬁcant effect on CAC
progression.
Houslay et al. (124) 2006 102 RCT Atorvastatin vs. placebo Statins had no signiﬁcant effect on rate of CAC progression.
Manson et al. (60) 2007 1,064 RCT Estrogen vs. placebo Women treated with estrogen had signiﬁcantly lower
calciﬁed plaque burden.
Maahs et al. (58) 2007 478 CS ACEi/ARB vs. other
antihypertensives
Diabetics with albuminuria had nonsigniﬁcant reduction in
CAC progression with ACEi/ARB treatment.
Qunibi et al. (62) 2008 203 RCT Calcium acetate/atorvastatin
vs. sevelamer/atorvastatin
Calcium acetate and sevelamer groups had comparable
rates of CAC progression in hemodialysis patients
at 1 year.
Budoff et al. (63) 2009 65 RCT AGE/vitamins B12 and B6/
folic acid/L-arginine vs. placebo
Treatment group experienced signiﬁcantly lower rates of
CAC progression at 1 year.
Zeb et al. (64) 2012 65 RCT AGE/CoQ10 vs. placebo AGE/CoQ10 was associated with signiﬁcantly lower rates
of CAC progression at 1 year.
ACEi ¼ angiotensin-converting enzyme inhibitor; AGE ¼ aged garlic extract; ARB ¼ angiotensin receptor blocker; CAC ¼ coronary artery calciﬁcation; Co ¼ coenzyme; CS ¼ case series; HCTZ ¼ hydro-
chlorothiazide; HRT ¼ hormonal replacement therapy; RCT ¼ randomized controlled trial.
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1708(odds ratio: 1.01, 95% conﬁdence interval: 0.85 to 1.21)
and MACE (odds ratio: 0.94, 95% conﬁdence interval:
0.78 to 1.14) compared with balloon angioplasty alone.
However, MI and vessel perforation were more common
with CBA (92).
Vaquerizo et al. (93) have more recently reported similar
acute and intermediate-term outcomes (at 15  11 months)
in calciﬁed lesions pre-treated with CBA compared with
RA before DES implantation. Whether these results apply
to the most heavily calciﬁed lesions is uncertain. Finally,Table 3 Outcomes of Studies Comparing DES and BMS in Calciﬁed L
First Author (Ref. #) Intervention
Follow-Up
(Months)
Resten
(%
Moussa et al. (74) PES 12 7.5
BMS 18.3
p value 0.1
Seo et al. (82) SES 6–9 8.8
BMS 33.3
p value <0.0
Khattab et al. (83)* DES 9 7.4
BMS 52.7
p value 0.0
Rathore et al. (84)* DES 6–9 11.0
BMS 28.1
p value <0.0
Bangalore et al. (81)* DES 12 d
BMS d
p value d
Schwartz et al. (125)* DES d
BMS In-hospital d
PTCA d
p value d
*Used rotational atherectomy.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); MACE ¼major adverse cardiovascular event(s)
coronary angioplasty; SES ¼ sirolimus-eluting stent(s); TLR ¼ target lesion revascularization.pre-dilation with a scoring balloon has been demonstrated to
enhance DES expansion (94). This device might be a useful
adjunct to PCI in calciﬁed lesions (95).
ROTATIONAL ATHERECTOMY. In contrast to cutting and
scoring balloons, high-speed RA ablates coronary calcium.
The RA device employs a diamond-coated elliptical burr,
which can reach rotational speeds as high as 200,000 rpm,
abrading hard tissue into smaller particles (<10 mm) while
deﬂecting off softer elastic tissue (96). This principle of
differential cutting was conﬁrmed by early IVUS-basedesions
osis
)
TLR
(%)
MI
(%)
Death
(%)
MACE
(%)
5.1 4.1 2.5 11.8
11.9 3.2 0.8 16.8
0 0.09 0.68 0.29 0.27
7.9 0.0 0.0 7.9
19.5 0.0 2.4 24.4
5 NS NS NS <0.05
7.4 0.0 0.0 7.4
35.2 2.9 2.9 38.2
008 0.006 0.4 0.4 0.004
10.6 d d d
25.0 d d d
01 0.001 d d d
d 5.6 3.9 d
d 5.8 4.9 d
d 0.90 0.35 d
d 2.7 0.9 3.6
d 0.0 5.3 5.3
d 0.0 11.1 14.8
d 1.0 0.0246 0.047
; MI ¼myocardial infarction(s); PES ¼ paclitaxel-eluting stent(s); PTCA ¼ percutaneous transluminal
Table 4 Studies of Cutting and Scoring Balloons in Calciﬁed Coronary Lesions
First Author (Ref. #) Year N Design Intervention Outcomes
Okura et al. (126) 2002 224 RCT CBA vs. PTCA CBA was associated with signiﬁcantly greater lumen
cross-sectional area gain than PTCA in calciﬁed lesions.
Dissections were more common with CBA.
de Ribamar Costa et al. (94) 2007 299 CS DES vs. SBA/DES vs.
semi-compliant balloon/DES
SBA was associated with greater stent expansion compared
with direct stenting or stenting with pre-dilation with
conventional balloons.
Grenadier et al. (95) 2008 521 CS SBA þ PTCA SBA was associated with high rates of procedural success
(97.9%), with low rates of short- and long-term adverse
outcomes.
Vaquerizo et al. (93) 2010 145 CS RA  CBA þ DES Low rates of TLR and ST were observed with CBA alone and
RAþCBA in patients receiving DES at 15  11 months.
Only studies with 100 patients were included.
CBA ¼ cutting balloon atherotomy; RA ¼ rotational atherectomy; SBA ¼ scoring balloon angioplasty; ST ¼ stent thrombosis; other abbreviations as in Table 2 and 3.
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1709studies (97,98), which demonstrated that RA preferentially
ablates calcium deposits.
Studies assessing high-speed RA are summarized in
Table 5. In the pre-stent era, use of RA alone was associated
with increased neointimal hyperplasia, restenosis, and repeat
revascularization, most likely due to platelet activation and
thermal injury (99–101). Moreover, patients with calciﬁed
lesions undergoing RA are at increased risk for thrombus
formation and slow or no reﬂow, with increased rates of
periprocedural MI (78). Although slow, deliberate passes
with or without glycoprotein IIb/IIIa inhibitors can reduce
the burden of microparticle embolization, the risk of vessel
perforation after RA in complex calciﬁed lesions is also
increased (102).
BMS implantation after RA in calciﬁed lesions facilitates
greater acute lumen gains, although restenosis rates
remained high (68,103,104). DES use after RA has been
associated with better long-term outcomes (83,84), althoughTable 5 Studies of High-Speed RA in Calciﬁed Coronary Lesions
First Author (Ref. #) Year N Design Intervention
Ellis et al. (99) 1994 316 MR RA and PTCA
Warth et al. (100) 1994 709 MR RA  PTCA
MacIsaac et al. (101) 1995 2,161 MR RA and PTCA
Hoffmann et al. (68) 1998 323 CS RA and BMS
Kobayashi et al. (104) 1999 126 CS RA and BMS
Dill et al. (127) 2000 502 RCT RA and PTCA
Whitlow et al. (128) 2001 500 RCT RA  PTCA
Clavijo et al. (105) 2006 150 CS RA and DES
Mezilis et al. (106) 2010 150 CS RA and DES
Rathore et al. (84) 2010 516 CS RA and
DES vs. BMS
Schwartz et al. (125) 2011 158 CS RA and
BMS or DES
Benezet et al. (107) 2011 102 CS RA and DES
Naito et al. (129) 2012 233 CS RA and DES
Abdel-Wahab et al. (75) 2013 240 RCT RA and DES
Only studies with 100 patients were included.
MR ¼ multicenter registry; other abbreviations as in Tables 2 to 4.case series reported inconsistent results (105–107). Recently,
the prospective, randomized ROTAXUS (Rotational
Atherectomy Prior to Taxus Stent Treatment for Complex
Native Coronary Artery Disease) trial was performed to
determine whether lesion preparation with RA before
paclitaxel-eluting stent (PES) implantation provides beneﬁts
compared with PES with balloon pre-dilation alone in
calciﬁed lesions (75). Among 240 patients with complex
calciﬁed lesions randomized to RA or standard therapy
followed by PES, strategy success was higher with RA pre-
treatment (92.5% vs. 83.3%; p ¼ 0.03). However, despite an
early acute lumen gain advantage with RA, 9-month
angiographic follow-up revealed higher late loss in the RA
group. Rates of restenosis, target lesion revascularization,
deﬁnite stent thrombosis, and MACE were not signiﬁcantly
different between the groups.
Thus, RA cannot routinely be recommended in calciﬁed
lesions if full balloon expansion is anticipated before DESOutcomes
Greater procedural success compared with reports with PTCA alone.
Comparable success rates between RA and adjunctive PTCA.
No difference in procedural success or adverse outcome rates between
calciﬁed and noncalciﬁed lesions with RA and adjunctive PTCA.
Greater acute lumen gain and ﬁnal residual stenosis with adjunctive RA.
Lower restenosis rates with aggressive compared with less aggressive RA.
RA/PTCA vs. PTCA showed comparable rates of procedural success and
adverse outcomes.
Aggressive RA with minimal ballooning offers no advantage over standard burr
sizing followed by PTCA.
No difference in 6-month outcomes.
RA and DES showed low rates of adverse outcomes in heavily calciﬁed lesions
up to 6 years.
RA with DES showed signiﬁcantly lower rates of restenosis and TLR compared
with BMS.
Procedural success with RA/stent placement higher than RA alone.
RA with DES has high procedural success and low rates of adverse outcomes.
No difference in TLR, all-cause or cardiac death, or MACE between PES and SES.
Greater acute gain but no difference in 9-month outcomes.
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reasonable strategy in calciﬁed lesions that are not crossable
by a balloon catheter or adequately dilated before stent
implantation (Class IIa, Level of Evidence: C) (108). Lesion
preparation with RA before PCI is currently performed
in approximately 8% of cases with calciﬁed lesions in the
United States (81). Additional studies are required to
determine the extent of calciﬁcation that necessitates RA
before stenting.
LASER CORONARY ATHERECTOMY. Pulsed excimer or holmi-
um laser energy generates transient high-pressure waves,
which can dilate resistant lesions through a photoacoustic
mechanism (109–111). Studies evaluating laser coronary
atherectomy (LCA) in calciﬁed and noncalciﬁed lesions
(Table 6) show inconsistent results and the potential for
procedural complications such as vessel dissection (especially
with superﬁcial calcium) and perforation and higher rates of
restenosis (112,113). Furthermore, IVUS has not shown
qualitative or quantitative evidence of substantial calcium
ablation by LCA (114). Nonetheless, LCA has a role in
calciﬁed lesions to shatter calcium behind previously-
implanted stent struts in cases of marked stent under-
expansion (115).
ORBITAL ATHERECTOMY. Similar to RA, orbital atherectomy
(OA) exerts a differential ablative effect on hard and soft
surfaces, producing particles <2 mm in size. This recently
U.S. Food and Drug Administration-approved system
consists of a diamond-coated crown, which orbits over the
atherectomy guidewire in an elliptical path, exerting a cen-
trifugal force on the vessel wall (116). In contrast to RA, the
ablative element is located laterally on the coil, which con-
sists of 3 helically-wound wires that can be compressed with
the application of pressure like a spring. The device allows
the physician to control ablation depth, with increasing
rotational speed (ranging from 60,000 to 120,000 rpm)Table 6 Studies of Laser Coronary Angioplasty in Calciﬁed Coronary
First Author (Ref. #) Year N Design Intervention
Ghazzal al. (130) 1992 200 MR ELCA and PTCA
Bittl et al. (113) 1992 764 MR ELCA and PTCA
Bittl and Sanborn (131) 1992 200 MR ELCA and PTCA
Baumbach et al. (132) 1994 470 MR ELCA and PTCA
Mintz et al. (114) 1995 190 CS ELCA and
PTCA or DCA
Reifart et al. (133) 1997 685 RCT ELCA, RA, or PTCA
Stone et al. (134) 1997 215 RCT HLCA and PTCA
Appelman et al. (135) 1998 308 RCT ELCA and PTCA
Badr et al. (136) 2013 119 CS ELCA  PTCA
Only studies with 100 patients were included.
DCA ¼ directional coronary atherectomy; ELCA ¼ excimer laser coronary angioplasty; HLCA ¼ holmiutranslating to a larger orbit of rotation. In addition, orbital
motion might allow for greater blood ﬂow with less heat
generation and thermal injury during the procedure (116).
Like RA, OA might improve the compliance of calciﬁed
lesions to reduce procedural complications and facilitate
stent placement.
After the ORBIT I (Safety and Feasibility of Orbital
Atherectomy for the Treatment of Calciﬁed Coronary Le-
sions) pilot study (116), 443 patients with severely calciﬁed
coronary lesions were enrolled in the prospective, single-arm
ORBIT II study (Pivotal Trial to Evaluate the Safety and
Efﬁcacy of the Diamondback 360 Orbital Atherectomy
System in Treating De Novo, Severely Calciﬁed Coronary
Lesions) (117). The in-hospital mortality rate after OA of
0.2% compares favorably with the 1.7% rate after RA in the
ROTAXUS trial (75). The 89.8% primary safety endpoint
of 30-day freedom from MACE and 89.1% procedural
success rate both exceeded performance goals. Future ran-
domized studies are planned to evaluate the optimal tech-
nique for OA use and to determine whether routine use of
OA before current-generation DES improves outcomes in
high-risk patients with CAC.
Coronary artery bypass graft surgery. Calciﬁed vessels
pose a technical challenge for the surgeon. Severely calciﬁed
lesions have been associated with atheroembolic complica-
tions and incomplete revascularization after coronary artery
bypass graft surgery (CABG), resulting in worse outcomes
in high-risk patients (118,119). Additionally, patients with
CAC are more likely to develop calciﬁed saphenous vein
grafts, a strong predictor of early and late graft failure (120).
Among 755 patients with non–ST-segment acute coronary
syndromes undergoing CABG in the prospective ACUITY
(Acute Catheterization and Urgent Intervention Triage
strategY) trial, severe CAC was independently associated
with the occurrence of death or MI and MACE at 1 year
(121). Thus, CAC impairs the results of both PCI andLesions
Outcomes
No difference in outcomes in calciﬁed lesions treated with ELCA before PTCA.
High rate of restenosis (43%) in calciﬁed lesions at 6 months. Signiﬁcant increase
in rate of complications in calciﬁed vs. noncalciﬁed lesions at 6 months.
Nonsigniﬁcant reduction in procedural success in calciﬁed lesions.
No difference in rates of complications in calciﬁed vs. noncalciﬁed lesions treated
with ELCA before PTCA.
Increase in lumen cross-sectional area without calcium ablation and with high rate
of dissection (39%).
Greatest procedural success in RA group. Higher TLR with ELCA and RA.
Comparable rates of procedural success and long-term outcomes but greater rates
of in-hospital complications, MI, and MACE in those treated with HLCA before
PTCA than PTCA alone.
ELCA with adjunctive PTCA demonstrated no difference in 6-month outcomes
compared with PTCA alone in calciﬁed lesions.
Lower rates of angiographic success in calciﬁed lesions compared with other
lesion types.
m laser coronary angioplasty; other abbreviations as in Tables 2 to 5.
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revascularization strategies and improve outcomes in pa-
tients with severe CAC.
Conclusions and Future Directions
Patients with CAC are at high risk for the development of
symptomatic CAD and MACE. Statins have not been
shown to halt the progression or affect the natural history of
CAC. Further studies are needed to determine whether
novel systemic therapies beneﬁt patients with CAC. Among
patients undergoing PCI, calciﬁcation proximal to and at the
target lesion site directly contributes to suboptimal proce-
dural results and worsened long-term outcomes. Although
the advent of DES has led to improved outcomes after PCI
of CAC, long-term MACE rates remain high. Currently,
adjunctive devices to improve lesion compliance, debulk
plaque, and otherwise prepare the lesion for stenting are
reserved for heavily calciﬁed lesions and for those in which
stent delivery or expansion is otherwise anticipated to be or
found to be difﬁcult. As such, many patients with heavy
CAC are referred to CABG, especially if the distal coronary
anastomotic target segments are not heavily diseased or
calciﬁed. Nevertheless, severe CAC poses technical chal-
lenges to the surgeon as well, and results are suboptimal.
Further advances are needed in the early diagnosis, pre-
vention, and treatment of CAC. Deeper understanding of
the fundamental mechanisms underlying the pathogenesis
and progression of CAC and its relationship with advanced
atherosclerosis is necessary. Standardized screening in the
general population with improved calcium detection might
improve outcomes if effective preventative therapies are
developed. At a minimum, the presence of CAC on CT
imaging should prompt aggressive risk factor and lifestyle
modiﬁcation. In patients undergoing PCI of heavily calciﬁed
lesions, optimized methods of lesion preparation and cal-
cium ablation are needed, as are safer and more effective
antiproliferative therapies. In this regard, it has already been
suggested that bioresorbable vascular scaffolds might be
useful for calciﬁed lesions (122), although optimal lesion
preparation will be essential, given their greater proﬁle and
propensity to recoil. In the future, the societal impact of
CAC is likely to increase with an aging population, placing
a premium on developing effective therapeutic strategies
for this pandemic condition.
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